- Home
- MIN vs XOMA Comparison
MIN vs XOMA Comparison
Compare MIN & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | XOMA |
|---|---|---|
| Founded | 1988 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.7M | 397.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MIN | XOMA |
|---|---|---|
| Price | $2.62 | $25.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $63.25 |
| AVG Volume (30 Days) | ★ 331.0K | 78.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.08 | ★ 0.82 |
| Revenue | N/A | ★ $47,106,000.00 |
| Revenue This Year | N/A | $77.23 |
| Revenue Next Year | N/A | $17.97 |
| P/E Ratio | $33.38 | ★ $32.30 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $2.52 | $18.35 |
| 52 Week High | $2.88 | $39.92 |
Technical Indicators
Market Signals| Indicator | MIN | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 32.37 |
| Support Level | $2.60 | $29.60 |
| Resistance Level | $2.67 | $34.79 |
| Average True Range (ATR) | 0.03 | 1.86 |
| MACD | -0.00 | -0.39 |
| Stochastic Oscillator | 28.57 | 1.19 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.